For example, the main indications for the treatment with Pembrolizumab, a PD-L1 inhibitor, are: (1) as a first-line therapy for metastatic NSCLC with PD-L1 TPS ≥ 50% and (2) treatment for patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥ 1%), with disease progression or after chemotherapy [8]. Here, CD274 is linked to non-small cell lung carcinoma.